Tag: hematology
ASH 2020: Potential of Belantamab Mafodotin in Combination Standard Therapies in...
Multiple myeloma is the second most common hematological malignancy in the United States and is generally considered treatable, but not curable. Multiple myeloma...
TRPH-222, a Novel Anti-CD22 ADC, has Significant Anti-Tumor Activity in NHL
A preclinical abstract describing TRPH-222, also known as CAT-02-106, an anti-CD22 antibody-drug conjugate or ADC being developed by Triphase Accelerator for the treatment of...
Antibody-drug Conjugate Targeting CD46 Eliminates Multiple Myeloma Cells
Authors: Sherbenou DW , Aftab BT , Su Y, Behrens CR , Wiita A, Logan AC , Acosta-Alvear D, Hann BC , Walter...
Preclinical Data of Novel Antibody-drug Conjugate IMGN779 Demonstrates Potent Activity Against...
Results from a preclinical trial shows that IMGN779, a novel, DNA-alkylating, anticancer therapeutics based on ImmunoGen, Inc, antibody-drug conjugates (ADC) technology, shows potent activity against CD33-expressing acute myeloid leukemia cells,including leukemic stem cells, while sparing normal cells.
Clinical Trial with Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin...
Earlier today, Pfizer Inc. confirmed that it had discontinued a Phase III randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the...
New CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Anti-tumor Activity in...
Preclinical data from SGN-CD33A (Seattle Genetics, Inc), a novel CD33-directed antibody-drug conjugate (ADC) in development for the treatment of acute myeloid leukemia (AML) presented at...
Novel Drugs Breaks Down Barriers – Attacks Breast Cancer Cells from...
Throwing stones at castle walls is one way to attack an enemy, but sneaking inside makes the target much more vulnerable. Researchers at Cedars-Sinai's...
